| Filed On | Filing |
|---|---|
| 13 Nov 2026 | SCHEDULE 13G/A |
| 12 Nov 2026 | S-3 |
| 12 Nov 2026 | 10-Q |
| 12 Nov 2026 |
8-K: Results of Operations and Financial Condition
First participant dosed in Phase 1 clinical trial of EQ504, proof-of-mechanism data expected in Q2 2027 |
| 12 Nov 2026 | SCHEDULE 13G/A |
| 04 Nov 2026 | SCHEDULE 13G/A |
| 26 Oct 2026 |
8-K: Unregistered Sales of Equity Securities; Regulation FD Disclosure +1 more
Topline Phase 1 proof-of-mechanism data anticipated in Q2 2027 |
| 05 Oct 2026 |
8-K: Other Events
On October 5, 2026, Equillium, Inc. (the Company) announced that the Company has received Human Research Ethics Committee approval and clearance from the Therapeutic Goods Administration in Australia under the Clinical Trial Notification... |
| 13 Aug 2026 | 10-Q |
| 13 Aug 2026 | SCHEDULE 13G |
| 13 Aug 2026 |
8-K: Results of Operations and Financial Condition
Phase 1 proof-of-mechanism study of EQ504 initiation expected in Q4 2026, with data expected approximately six months thereafter |
| 12 Aug 2026 | SCHEDULE 13G/A |
| 05 Jun 2026 | 144 |
| 05 Jun 2026 |
Form 4: Zedelmayer Christine, Sr. Vice President and COO
Received 14,584 shares by exercise or conversion ($11.4K) · Sold 14,584 shares ($42.7K) |
| 05 Jun 2026 |
Form 4: Connelly Stephen, President and CSO
Sold 200,000 shares ($633K) · Sold 30,975 shares ($91.1K) |
| 04 Jun 2026 | 144 |
| 29 May 2026 |
Form 4: Tom Penny, Principal Accounting Officer
Received 65,000 shares by exercise or conversion ($51K) · Sold 65,000 shares ($192K) |
| 29 May 2026 |
Form 4: Demski Martha J, Director
Granted 70,000 Director Stock Option (right to buy) |
| 29 May 2026 |
Form 4: Pruzanski Mark, Director
Granted 70,000 Director Stock Option (right to buy) |
| 29 May 2026 |
Form 4: Bradbury Daniel, Director
Granted 70,000 Director stock option (right to buy) |
Loading...